Determination of drug content in semisolid formulations by non-invasive spectroscopic methods: FTIR – ATR, – PAS, – Raman and PDS

Gotter, B.; Faubel, W.; Heissler, S.; Hein, Joachim; Neubert, Reinhard H.H.

doi:10.1088/1742-6596/214/1/012129

Cited by 7 publications

(3 citation statements)

References 5 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…The quantitative Raman assays have also been developed for various solid drug dosing formats, such as capsules, tablets, and powders [ 47 , 48 , 49 ]. In addition, Gotter et al [ 50 ] have described the use of Raman spectroscopy for the quantification of a drug suspended in a simple semi-solid formulation consisting of paraffin. More complex solid pharmaceutical formulations were analyzed by Hargreaves et al [ 51 ], who established Raman spectroscopy for the quantitative analysis of multi-component pharmaceutical capsules.…”

Section: Introductionmentioning

confidence: 99%

Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for the Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs

2021

View full text Add to dashboard Cite

Safe administration of highly cytotoxic chemotherapeutic drugs is a challenging problem in cancer treatment due to the adverse side effects and collateral damage to non-tumorigenic cells. To mitigate these problems, promising new approaches, based on the paradigm of controlled targeted drug delivery (TDD), and utilizing drug nanocarriers with biorecognition ability to selectively target neoplastic cells, are being considered in cancer therapy. Herein, we report on the design and testing of a nanoparticle-grid based biosensing platform to aid in the development of new targeted drug nanocarriers. The proposed sensor grid consists of superparamagnetic gold-coated core–shell Fe2Ni@Au nanoparticles, further functionalized with folic acid targeting ligand, model thiolated chemotherapeutic drug doxorubicin (DOX), and a biocompatibility agent, 3,6-dioxa-octanethiol (DOOT). The employed dual transduction method based on electrochemical and enhanced Raman scattering detection has enabled efficient monitoring of the drug loading onto the nanocarriers, attaching to the sensor surface, as well as the drug release under simulated intracellular conditions. The grid’s nanoparticles serve here as the model nanocarriers for new TDD systems under design and optimization. The superparamagnetic properties of the Fe2Ni@Au NPs aid in nanoparticles’ handling and constructing a dense sensor grid with high plasmonic enhancement of the Raman signals due to the minimal interparticle distance.

show abstract

Section: Introductionmentioning

confidence: 99%

Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for the Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs

2021

View full text Add to dashboard Cite

show abstract

“…The quantitative Raman assays have also been developed for various solid drug dosing formats, such as capsules, tablets, and powders [44][45][46][47][48]. In addition, Gotter et al [49] have described the use of Raman spectroscopy for the quantification of a drug suspended in a simple semi-solid formulation consisting of paraffin. More complex solid pharmaceutical formulations were analyzed by Hargreaves et al [50], who established Raman spectroscopy for quantitative analysis of multi-component pharmaceutical capsules.…”

Section: Introductionmentioning

confidence: 99%

Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs

Ilkhani¹,

Zhong²,

Hepel³

2021

Preprint

View full text Add to dashboard Cite

Safe administration of highly cytotoxic chemotherapeutic drugs is a challenging problem in cancer treatment due to the adverse side effects and collateral damage to non-tumorigenic cells. To mitigate these problems, new promising approaches, based on the paradigm of controlled targeted drug delivery (TDD), utilizing drug nanocarriers with biorecognition ability to selectively target neoplastic cells, are being considered in cancer therapy. Herein, we report on the design and testing of a nanoparticle-grid based biosensing platform to aid in the development of new targeted drug nanocarriers. The proposed sensor grid consists of superparamagnetic gold-coated core-shell Fe2Ni@Au nanoparticles, further functionalized with folic acid targeting ligand, model thiolated chemotherapeutic drug doxorubicin (DOX), and a biocompatibility agent, 3,6,-dioxa-octanethiol (DOOT). The employed dual transduction based on electrochemical and enhanced Raman scattering detection have enabled efficient monitoring of the drug loading onto the nanocarriers, attached to the sensor surface, as well as the drug release under simulated intracellular conditions. The grid’s nanoparticles serve here as the model nanocarriers for new TDD systems under design and optimization. The superparamagnetic properties of the Fe2Ni@Au NPs aid in nanoparticles’ handling and constructing a dense sensor grid with high plasmonic enhancement of the Raman signals due to the minimal interparticle distance.

show abstract

“…A PAT-technique frequently proposed for API quantification is Raman spectroscopy. For semi-solid formulations, some off-line quantitative applications have been reported (De Beer et al, 2007;Gotter et al, 2010;Islam et al, 2004;Mazurek and Szostak, 2016;Oh et al, 2010). Raman spectroscopy was investigated in these studies as alternative to replace the standard analytical methods since the technique is fast, nondestructive and samples can be measured without prior manipulation by preparation procedures.…”

Section: Introductionmentioning

confidence: 99%

PAT-based batch statistical process control of a manufacturing process for a pharmaceutical ointment

Bostijn

Dhondt

Vervaet

et al. 2019

European Journal of Pharmaceutical Sciences

View full text Add to dashboard Cite

Determination of drug content in semisolid formulations by non-invasive spectroscopic methods: FTIR – ATR, – PAS, – Raman and PDS

Cited by 7 publications

References 5 publications

Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for the Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs

Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for the Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs

Magneto-Plasmonic Nanoparticle Grid Biosensor with Enhanced Raman Scattering and Electrochemical Transduction for Development of Nanocarriers for Targeted Delivery of Protected Anticancer Drugs

PAT-based batch statistical process control of a manufacturing process for a pharmaceutical ointment

Contact Info

Product

Resources

About